Invex Therapeutics Ltd. (AU:IXC)
ASX:IXC
Want to see AU:IXC full AI Analyst Report?
IXC Stock Chart & Stats
AU$0.12
AU$0.00(0.00%)
At close: 4:00 PM EST
AU$0.12
AU$0.00(0.00%)
Day’s Range― - ―
52-Week RangeAU$0.08 - AU$0.18
Previous CloseN/A
Volume14.00K
Average Volume (3M)49.57K
Market Cap
AU$7.52M
Enterprise ValueAU$5.17M
Total Cash (Recent Filing)AU$5.38M
Total Debt (Recent Filing)AU$0.00
Price to Earnings (P/E)―
Beta0.41
Next Earnings
Aug 13, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding75,153,850
10 Day Avg. Volume15,093
30 Day Avg. Volume49,574
Financial Highlights & Ratios
PEG Ratio0.20
Price to Book (P/B)1.28
Price to Sales (P/S)29.41
P/FCF Ratio-10.32
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Debt-free Balance SheetZero debt reduces financial fragility and lowers fixed financing obligations, giving management flexibility to fund clinical programs or negotiate non-dilutive partnerships. A conservatively positioned balance sheet supports continuity of R&D over the medium term compared with levered peers.
Focused Clinical-stage PipelineA clear, concentrated R&D strategy around a lead IIH program concentrates resources and expertise, improving development execution probability. In clinical-stage biotech, a focused pipeline can create material value on positive clinical/regulatory milestones and attract targeted partnerships.
Improving Cash Outflow TrendsNarrowing losses and reduced cash outflows indicate better cost discipline or program prioritization, extending operational runway and reducing near-term refinancing pressure. If sustained, this trend materially lowers dilution risk and supports longer-term development plans.
Bears Say
Steep, Volatile Revenue DeclineAn ~81% YoY revenue drop and historically small, volatile sales demonstrate the absence of stable commercial cash flow, limiting the firm's ability to self-fund development. Persistent revenue volatility increases reliance on external financing and raises execution risk over the medium term.
Consistent Negative Cash GenerationRepeated negative operating and free cash flows mean the company must access capital markets or partners to continue development. This structural cash burn creates ongoing dilution potential, constrains strategic flexibility, and risks program delays if funding conditions worsen.
Equity Erosion And Negative ROEDeclining equity and persistently negative ROE signal shareholder value erosion from ongoing losses. Over time this weakens capital cushions, can worsen financing terms, and increases the chance of dilutive raises or asset sales to sustain R&D activities, impairing long-term investor returns.
Invex Therapeutics Ltd. News
IXC FAQ
What was Invex Therapeutics Ltd.’s price range in the past 12 months?
Invex Therapeutics Ltd. lowest share price was AU$0.07 and its highest was AU$0.18 in the past 12 months.
What is Invex Therapeutics Ltd.’s market cap?
Invex Therapeutics Ltd.’s market cap is AU$7.52M.
When is Invex Therapeutics Ltd.’s upcoming earnings report date?
Invex Therapeutics Ltd.’s upcoming earnings report date is Aug 13, 2026 which is in 46 days.
How were Invex Therapeutics Ltd.’s earnings last quarter?
Invex Therapeutics Ltd. released its earnings results on Feb 12, 2026. The company reported -AU$0.01 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.01.
Is Invex Therapeutics Ltd. overvalued?
According to Wall Street analysts Invex Therapeutics Ltd.’s price is currently Overvalued.
Does Invex Therapeutics Ltd. pay dividends?
Invex Therapeutics Ltd. pays a Notavailable dividend of AU$0.186 which represents an annual dividend yield of N/A. See more information on Invex Therapeutics Ltd. dividends here
What is Invex Therapeutics Ltd.’s EPS estimate?
Invex Therapeutics Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Invex Therapeutics Ltd. have?
Invex Therapeutics Ltd. has 75,153,850 shares outstanding.
What happened to Invex Therapeutics Ltd.’s price movement after its last earnings report?
Invex Therapeutics Ltd. reported an EPS of -AU$0.01 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 4.167%.
Which hedge fund is a major shareholder of Invex Therapeutics Ltd.?
Currently, no hedge funds are holding shares in AU:IXC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Invex Therapeutics Ltd. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
33.72%
12-Months-Change
Fundamentals
Return on Equity
-17.07%
Trailing 12-Months
Asset Growth
-19.46%
Trailing 12-Months
Company Description
Invex Therapeutics Ltd.
Invex Therapeutics Ltd is an Australian biopharmaceutical company dedicated to researching and developing innovative treatments for various neurological disorders. Their primary focus is Exenatide, a promising therapeutic agent aimed at neurological conditions linked to or resulting from elevated intracranial pressure, including idiopathic intracranial hypertension, acute stroke, and traumatic brain injury. Exenatide has successfully advanced through Phase II clinical trials. The company was founded in 2019 and operates from Perth, Australia.
Technical Analysis
Alterity Therapeutics
―
AnteoTech Ltd
―
AdAlta Ltd.
―
Chimeric Therapeutics Ltd.
―
Recce Pharmaceuticals Ltd.
―